Most interestingly, we identified one such TED IV‐255 whose activity was totally dependent on BRG1 but not BRM expression by a CRISPR/Cas9 gene editing to knockout BRG1 expression in established GBM cell lines. Here, SMARCA2 is linked to glioblastoma.